OC
ZYNE

Oakworth Capital’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Oakworth Capital’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,965
Closed -$11K – 662
2019
Q1 		$11K Buy
+1,965
New +$9.56K ﹤0.01% 446

Other funds holding ZYNE

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
ZCA
Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Oakworth Capital's ZYNE Position: Q2 2019 in Review

Oakworth Capital sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q2 2019, closing a stake of 1,965 shares — an estimated $11K sold.

Oakworth Capital first reported a position in ZYNE in Q1 2019 and held it in 1 quarter. The position peaked at $11K in Q1 2019. 76 funds tracked by Wall St. Rank hold ZYNE as of Q2 2019.

  • Oakworth Capital reported no remaining Zynerba Pharmaceuticals, Inc position as of Q2 2019 after selling out during the quarter.
  • Oakworth Capital sold 1,965 Zynerba Pharmaceuticals, Inc shares in Q2 2019, an estimated $11K.
  • Oakworth Capital first reported a position in Zynerba Pharmaceuticals, Inc in Q1 2019 and held it in 1 quarter.
  • Oakworth Capital's Zynerba Pharmaceuticals, Inc position peaked at $11K in Q1 2019.
  • 76 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q2 2019.

Based on Oakworth Capital's 13F filing for Q2 2019, filed 2 Aug 2019.